盐酸氨溴索联合利奈唑胺治疗重症肺炎患者的效果

Effect of Ambroxol Hydrochloride Combined with Linezolid in the Treatment of Severe Pneumonia

目的观察盐酸氨溴索联合利奈唑胺治疗对重症肺炎患者炎症反应及肺功能的影响。方法选取2020年6月至2021年6月于南阳医学高等专科学校附属中医院进行治疗的重症肺炎患者中选择100例为本研究对象,按照随机数字表法分为两组,50例患者接受利奈唑胺治疗(对照组),50例患者接受盐酸氨溴索联合利奈唑胺治疗(联合组)。检测患者的血清高迁移率族蛋白B1(HMGB1)、溶性髓样细胞触发受体-1(sTREM-1)、白细胞介素-1β(IL-1β)水平,测定患者的第1秒用力呼气量(FEV1)、最大呼气中期流速(MMF)、用力肺活量(FVC)、FEV1/FVC等肺功能指标,记录两组患者发生视力障碍、头晕、骨髓抑制及腹泻等不良反应的情况,比较两组疗效。结果两组治疗后的HMGB1、sTREM-1、IL-1β水平较治疗前降低(P<0.05),联合组治疗后的HMGB1、sTREM-1、IL-1β水平低于对照组(P<0.05);两组治疗后的FEV1、MMF、FVC、FEV1/FVC较治疗前升高(P<0.05),联合组治疗后的FEV1、MMF、FVC、FEV1/FVC高于对照组(P<0.05);联合组不良反应总发生率为6.00%,低于对照组(26.00%)(P<0.05);联合组总有效率为96.00%,高于对照组(84.00%)(P<0.05)。结论盐酸氨溴索联合利奈唑胺治疗重症肺炎患者的临床效果较好,可下调HMGB1、sTREM-1、IL-1β水平,抑制炎症反应,改善其肺功能,还能减少不良反应事件的发生。

Objective To observe the effect of ambroxol hydrochloride combined with linezolid on inflammatory response and pulmonary function in patients with severe pneumonia.Methods A total of 100 patients with severe pneumonia who were treated in Affiliated Hospital of Traditional Chinese Medicine of Nanyang Medical College from June 2020 to June 2021 were selected.According to the random number table method,they were divided into two groups,50 patients were treated with linezolid(control group),and 50 patients were treated with ambroxol hydrochloride combined with linezolid(combination group).The patient’s serum human high-mobility group box-1(HMGB1),serum lytic myeloid cell trigger receptor-1(sTREM-1),interleukin-1β(IL-1β)levels were detected.The patient’s forced expiratory volume in one second(FEV 1),maximum mid-expiratory flow rate(MMF),forced vital capacity(FVC),FEV 1/FVC and other pulmonary function indicators were measured.The adverse reactions of the two groups of patients such as visual impairment,dizziness,bone marrow suppression and diarrhea were recorded.The efficacy of the two groups was compared.Results The levels of HMGB1,sTREM-1 and IL-1βin the two groups after treatment were lower than those before treatment(P<0.05),and the levels of HMGB1,sTREM-1 and IL-1βin the combined group after treatment were lower than those in the control group(P<0.05).After treatment,the FEV 1,MMF,FVC,FEV 1/FVC in the two groups were higher than those before treatment(P<0.05),and the FEV 1,MMF,FVC,FEV 1/FVC in the combined group after treatment were higher than those in the control group(P<0.05);The total incidence of adverse reactions in the combined group was 6.00%,which was lower than 26.00%in the control group(P<0.05).The total effective rate of the combined group was 96.00%,which was higher than the 84.00%of the control group(P<0.05).Conclusion Ambroxol hydrochloride combined with linezolid has a good clinical effect in the treatment of patients with severe pneumonia.It can down-regulate the levels of HMGB1,sTREM-1,and IL-1β,inhibit inflammation,improve lung function,and reduce the occurrence of adverse events.